A genetic variant c.553G&#8201;&gt;&#8201;T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug by N.M. Bogari et al.
Bogari et al. BMC Cardiovascular Disorders            (2019) 19:2 
https://doi.org/10.1186/s12872-018-0965-3RESEARCH ARTICLE Open AccessA genetic variant c.553G > T (rs2075291) in
the apolipoprotein A5 gene is associated
with altered triglycerides levels in coronary
artery disease (CAD) patients with lipid
lowering drug
Neda M. Bogari1*, Ashwag Aljohani1*, Amr A. Amin2,3, Faisal A. Al-Allaf1, Anas Dannoun1, Mohiuddin M. Taher1,4,
Atalla Elsayed5,6, Dareen ibrahim Rednah7, Osama Elkhatee8, Massimo Porqueddu9, Francesco Alamanni10,
Soud Abdulraof A. Khogeer2 and Ahmed Fawzy11*Abstract
Background: Elevated plasma triglycerides (TGs) are widely used as a major cardiovascular risk predictor and are
thought to play an important role in the progression of coronary heart disease (CHD). It has been demonstrated
that lipid lowering was associated with lower mortality in patients with CHD. The present study therefore aimed
to investigate the consequences of the genetic variant c.553G > T (rs2075291) in apolipoprotein A5 gene to
determination of triglycerides levels in CAD patients receiving, atorvastatin, lipid lowering drug.
Methods: We here report that a recently identified genetic variant, c.553G > T in the APOA5 gene which
causes a substitution of a cysteine for a glycine residue at amino acid residue 185(G185C) is also associated
with increased TG levels. To investigate theses effects, a case-control study compressing 608 subjects from the
same area was performed.
Results: TG levels in T allele patients were significantly lower than the control GT allele patient (χ2 = 2.382E2a,
P-value < 0.001). Overall, patients carrying T allele showed lower levels of TG than patients carrying GG allele.
The homozygous patient for the T allele presented normal cholesterol levels of 134 mg/dl, and the levels in
GG patients ranged from 25 to 340 mg/dl (P-value < 0.001). In summary, we demonstrated that the presence
of c.553G > T variant (rs2075291); in APOA5 gene increases human plasma TG levels.
Conclusion: Nevertheless, T allele is found to reduce TG levels in CAD patients who are on the cholesterol medication,
atorvastatin. Thus, c.553G > T variant can be considered as a significant predicator of hypertriglyceridemia. In addition, it
could be used as a hallmark for the diagnosis and prognosis of CAD.
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Coronary artery disease (CAD) is one of the most com-
monly diagnosed heart diseases. Diabetes, an elevation
in blood pressure and high-fat diets are considered as
some of the factors that contribute to the causation of
CAD [1]. Among these factors, an elevation in triglycer-
ides (TG) levels have shown a correlation with CAD oc-
currence although the exact mechanism is still obscure
[2]. Hypertriglyceridemia can develop as a result of pri-
mary factors including mainly genetics, or secondary fac-
tors such as diabetes and hyperlipidemia [2]. Genetic
abnormalities have contributed in causing hypertriglyc-
eridemia through influencing the metabolism of triglyc-
erides [3]. The overproductions of apo C-III through
genetic modifications and Lipoprotein lipase (LPL) have
shown an association with variations in triglycerides
levels [4].
Recently, the sequencing of human genomic DNA has
led to the discovery of Apolipoprotein A5 (APOA5) gene
which belongs to a regulatory gene family including
APOA1, APOC3 and APOA4 [5].This gene is located on
chromosome 11q23 in about 30 kb downstream of
APOA4, and contains four exons. Several studies have
indicated that the newly identified apolipoprotein locus
plays a major role in triglycerides hemostasis [6]. It en-
codes for apoA-V protein which reduces triglycerides
plasma levels [6]. Therefore, genetic alterations in
APOA5 could result in changes in TG levels. Point mu-
tations in APOA5 yield incomplete assembly of apoA-V
protein, and were observed mostly in patients with
hypertriglyceridemia. Nevertheless, no specific mutations
were known to cause severe illnesses, but certain studies
have predicted the association of single nucleotide poly-
morphisms (SNPs) in APOA5 with medical conditions.
The variants -1131 T > C and c.56C > G (S19W) for
APOA5s are examples of SNPs that have correlations
with high triglycerides plasma levels [7].Accordingly, A
novel variant c.553G > T was lately identified through
the sequencing of APOA5 coding region. This SNP
causes a substitution of the amino acid cysteine with a
glycine molecule [4]. The effect of which has been
researched and the conclusion is still to be reached. Upon
the effort to study c.553G > T variant, a very recent re-
search revealed that introducing a free cysteine in
APOA-V protein allows the binding of it with other pro-
teins through the formation of disulfide bonds which af-
fects TG modulation [8]. Furthermore, c.553G > T variant
(rs2075291); was detected in a higher rate in patients with
acute coronary syndrome when compared to the control
group [1]. Atorvastatin is a commonly known drug that is
used to regulate lipid metabolism [9]. Based on Biophar-
maceutics Classification System, atorvastatin is considered
as a class II drug [10], and is a member of statins family
also known as 3-hydroxy-3-methylglutaryl coenzyme Areductase inhibitors [11]. Therefore, atorvastatin is found
to reduce cholesterol levels in CAD patients. In a study
that was conducted to analyze the effects of atorvastatin
on various lipoproteins, atorvastatin showed no effects on
TG levels in Chylomicron, LDL, IDL and VLDL while it
reduced cholesterol levels in these lipoproteins [12]. Here,
we examine the effects of the genetic variant c.553G > T
(rs2075291); on TG levels in CAD patients receiving ator-
vastatin daily as a lipid lowering medicine.
Methods
Human subjects
This study was approved by the Institutional Review
Board and the Research ethics committees (REC) in
Umm al-Qura University medical school at Makkah,
Kingdom of Saudi Arabia. Blood was obtained from the
subjects after obtaining informed written consent from
the patients or their representatives. Patients with CAD
confirmed by coronary angiography (> 50% stenosis in
one or more arteries and stable or unstable angina pec-
toris) were enrolled in the study. Healthy controls from
the same area were also included. Most of these patients
were on appropriate and recommended doses of statin
therapy as per guidelines for the management of coron-
ary artery disease. The duration of therapy was not cap-
tured in current study.
All controls were examined clinically and investigated
by electrocardiography to exclude clinically apparent
CAD or other cardiovascular disease.
Laboratory analysis
An amount of 5 ml blood samples were obtained from
the subjects in the morning after an overnight fast.
Serum lipid parameters, including triglyceride (TG),
total cholesterol (TC), high-density lipoprotein choles-
terol (HDL-C) and low-density lipoprotein cholesterol
(LDL-C), apolipoprotein were measured by Dimension®
Clinical Chemistry System using Flex reagents.
DNA genotyping
Genomic DNA was extracted from peripheral blood
samples using GeneJET Whole Blood Genomic DNA
Purification kit (Thermo Scientific Co. Ltd.) and was
stored at − 20 °C. Genotyping for c.553G > T (rs2075291)
was performed by polymerase chain reaction (PCR) and
restriction enzyme digestion. The primers were as fol-
lows: Forward: 5′-AGA CAC CAA GGC CCA GTT
GCT GGG ‘3, Reverse: 5’-ATG CCG CTC ACC AGG
CTC TCG GCG ‘3. The PCR amplification was per-
formed in Veriti thermal cycler (Life technologies co.)
DNA was amplified using AmpliTaq Gold 360 Master
Mix (Life Technologies co.) under the following condi-
tions: initial denaturation at 95 °C for 5 min, followed by
37 cycles of 95 °C for 30 s, 58 °C for 30 s, and 72 °C for 1
Table 1 Baseline characteristics of CAD and control groups
CAD (354) Control (377) P-value
Age (years) 58.52 ± 11.10 37.3 ± 14.7 0.000
Gender (Male/ Female) 235/119 246/131 0.9009
Hypertension (n) 1.31 ± 0.51 1.78 ± 0.41 0.001
Glucose (mmol/ l) 1.39 ± 0.53 1.82 ± 0.38 0.000
HDL-C (mmol/ l) 1.37 ± 0.56 1.46 ± 0.63 0.103
LDL-C (mmol/ l) 1.65 ± 0.96 1.55 ± 0.80 0.191
Chol-C (mmol/ l) 1.17 ± 0.46 1.10 ± 0.36 0.041
TG-C (mmol/ l) 1.51 ± 0.82 1.16 ± 0.46 0.000
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These primers yielded a PCR fragment of 138 bp. Subse-
quently, 5 U of the enzyme HaeIII (New England Bio-
Labs Inc.) was added to 20 μl PCR products in a total
volume of 25 μl and incubated at 37 °C over night. After
restriction enzyme digestion, the products were sepa-
rated on a 3% agarose gel and visualized using ethidium
bromide and ultraviolet light. We found fragments of
138 and 87 bp for the GT heterozygotes, a single 138 bp
product for the TT homozygotes, and a single 87 bp
product for the GG homozygotes (Fig. 1).
Results
Baseline characteristics
Five hundred eighty five subjects including 247 females
(130 of them were considered as controls while 117 were
assigned as cases) and 338 males (107 of them were con-
trols while 231 were cases) were evaluated for this study.
The baseline characteristics of the CAD and control
groups are shown in Table 1. There was no statistical
significant difference in gender between the two groups.
However, the results showed a perceptible difference re-
garding to patients’ age even though the control group
was somewhat younger than CAD patients. Other pa-
rameters including blood pressure and glucose levels
were found to be higher in the control group than CAD
patients. Lipid parameters such as LDL and HDL levels
did not show any significant differences between the two
groups. Nevertheless, cholesterol and triglycerides levels
were higher in CAD patients than control group even
though some of them are on atorvastatin.
No statistical significant difference in gender between
the two groups. However, the results showed a percep-
tible difference regarding to patients’ age even though
the control group was somewhat younger than CADFig. 1 RFLP analysis result of APOA5 c.553G > T locus. The products
were separated on a 2% agarose gel and stained with ethidium
bromide. Lanes from 1 to 12; are considered as GG homozygous
(87 pb and 51 pb), Lanes; 13 and 14 are considered as GT heterozygose
(138 pb, 87 pb and 51 pb), Lane 14 is considered as TT homozygose
(138 pb)patients. Other parameters including blood pressure
and glucose levels were found to be higher in the con-
trol group than CAD patients. Lipid parameters such as
LDL and HDL levels did not show any significant dif-
ferences between the two groups. Nevertheless, choles-
terol and triglycerides levels were higher in CAD
patients than control group even though some of them
are on atorvastatin.
Relationship between T allele and triglycerides levels
TG levels in patients carrying the wildtype allele differ
depending on whether they are on atorvastatin, a drug
that lower cholesterol levels in the plasma, or not. CAD
patients who were on atorvastatin presented higher TG
levels than patients who were not on this drug (average
TG levels for both groups were 143.5 mg/dl and 125.8
mg/dl respectively). Regarding to the T allele presence,
two of the male patients have the T haplotype in
APOA5 gene while only one patient has TT allele.
One of the heterozygous GT allele patients and the
TT allele patient are on atorvastatin. On the other
hand, the other GT allele patient is not on atorva-
statin and is considered as a control in this study.
TG levels in T allele patients were significantly lower
than the control GT allele patient (χ2 = 2.382E2a,
P-value < 0.001). Overall, patients carrying T allele
showed lower levels of TG than patients carrying GG
allele. See Table 2.
Association of T allele with other lipid parameters
In addition to TG levels, low density lipoprotein (LDL),
High density lipoprotein (HDL) and cholesterol levels
were measured. Results from the analysis showed minorTable 2 TG levels in CAD patients separated by APOA5 genotype.
The wildtype represents GG allele while GT and TT alleles indicate
the presence of c.553G > T
Parameter ApoA5 genotypes P-value
GG GT TT
TG (mg/dl) 35–533 170–277 71–96 0.001
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minor T alleles. CAD patient carrying TT allele and GT
allele patient on Atorvastatin have normal LDL levels
(77 mg/dl and 45mg/dl) respectively. On the other hand,
CAD patient carrying GT allele but not on atorvastatin
has slightly high yet normal LDL level (158 mg/dl). LDL
levels vary in patients with the wildtype allele (11 to 199
mg/dl). There was no significant difference in HDL
levels between all CAD patients carrying GT and TT al-
leles, and the range of which varies from 32 to 44 mg/dl.
Finally, regarding to cholesterol levels in CAD patients
with the minor T allele, the patient with GT allele on
cholesterol medication has normal cholesterol level (111
mg/dl) while cholesterol level in the other GT patient
was high (258 mg/dl). The homozygous patient for the T
allele presented normal cholesterol levels of 134 mg/dl,
and the levels in GG patients ranged from 25 to 264mg/
dl (P-value < 0.001). See Fig. 2.
Association of T allele with other factors
Other parameters such as smoking status, diabetes and
exercising were included in this study. In T allele pa-
tients, the T allele homozygous patient is diabetic who
smokes and does not exercise. Conversely, the patients
who are heterozygous for the T allele were non-smokers,
non-diabetic and performed exercises. The differences in
previous parameters showed no significant effects on
their TG levels. Therefore, these parameters seem to
have no influence on the T allele presence. On the other
hand, there was a difference in the outcomes of patients
who were on aspirin. In T allele patients, the two pa-
tients who were taking Aspirin had lower TG levels of
71 and 170 mg/dl than the patient who was not taking
aspirin, the control. See Table 1. In addition, patients
with the wildtype allele and who were on aspirin andFig. 2 Lipid profiles levels in homozygous and heterozygous T allele
patients with CAD separated by APOA5 genotype. The variants (GT
and TT) are defined by the presence of c.553G > TSNPatorvastatin presented the lowest TG level of 35 mg/dl
when compared to GG patients who were either on as-
pirin or atorvastatin with TG levels of 40 and 37 mg/dl,
respectively. See Fig. 2 and Figs. 3, 4.Discussion
Our study validate the important role for CAD as the
most frequent cause of mortality across the world ac-
cording to data obtained from the World Health
Organization (WHO) [13]. Causes of such unfortunate
disease may be due to the complex interplay between
genetic risk factors and environmental exposures that
occur at critical times in development. Several epidemio-
logical studies have shown that apolipoprotein A1/C3/
A4/A5 gene cluster is found to be one of the factors that
could cause premature CAD [14]. Among the gene clus-
ter, APOA5 gene appears to affect TG levels [1]. Re-
cently, several SNPs found in APOA5 cause an elevation
in TG levels. A study has indicated that one of APOA5
SNPs, − 1131 T > C (rs2075291) variant, affects TG and
HDL levels; therefore, increases the risk of developing
cardiovascular diseases and diabetes [15]. Another study
has shown that upon the transduction of AAV2/8-LacZ,
AAV2/8-WT apoA-V and AAV2/8-G162C apoA-V, TG
levels were lower in the WT mice when compared to
both mutants [16]. In this study, we have described the
relevance between the variant G162C (corresponding to
c.553G > T) and TG levels in CAD patients who are on
atorvastatin daily.
The incidence of diabetes in general population in
Saudi Arabia is very high with up to 40% in some re-
ports. It is possibly that the control group has many un-
diagnosed, untreated or borderline patients. On the
other hand the CAD group most likely would be wellFig. 3 TG levels in homozygous G allele patients with CAD. Values
are separated into three groups depending on the type of
medications the patients are taking
Fig. 4 TG levels in CAD patients who have c.553G > T variant.
GT/ control represent a patient with GT haplotype and is not
taking atorvastatin or aspirin while GT and TT alleles carriers are
taking both atorvastatin and aspirin
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better.
Potential limitation of this study should be addressed.
As the number of patients in each cohort is small to
make conclusive results. Furthermore, there are differ-
ences between the control group and CAD group that
may affect the results. Larger number of patients with
TT allele is required to study in detail the effect of statin
therapy on TG levels. Additionally, the duration and re-
sponse to treatment was not studied in this report.
The frequency of c.553G > T allele in CAD patients
was higher than normal subjects. Normally, the presence
of T allele raises TG levels; yet, in patients carrying this
allele and are on atorvastatin, it seems to lower TG
levels. However, in a previous study, Ikejiri et al., stated
that atorvastatin has no reduction effects on TG rich li-
poproteins [12]. That conclusion is true regarding to the
findings of TG levels in GG allele patients which showed
no direct effects of atorvastatin on TG levels. In
addition, there were no substantial differences in LDL
between patients carrying T allele or the wildtype allele.
Recent studies have revealed that APOA5 could affect
cholesterol homeostasis and could cause hypertriglyc-
eridemia [17]. Recent studies have revealed that APOA5
could affect cholesterol homeostasis and could cause
hypertriglyceridemia [17] it is possible that statin therapy
in these patients have more effect on TG metabolism
given its effect on cholesterol hemostasis. Further mech-
anistic studies needs to be done on these patients. An-
other study that included Chinese subjects has shown
that in CAD patients and control groups, the wild type
GG carriers have considerably lower TG levels in com-
parison to the T allele carriers [18]. Regarding to HDLlevels in the study subjects, T allele patients who were
on atorvastatin have lower HDL levels than the other T
allele patient who was not taking atorvastatin, but all re-
sults were in the normal range. This has been proven
earlier by another Chinese study that showed no signifi-
cant associations between the presence of T allele and
lipid parameters including LDL, TC, and HDL [19]. As
expected, cholesterol levels in T allele patients on ator-
vastatin were normal and lower than the T allele patient
who was not on atorvastatin. This result is due to the
fact that the pharmacological effect of atorvastatin is to
lower cholesterol levels in the plasma. Previous studies
have confirmed that atorvastatin reduces both LDL and
total cholesterol, and it decreases cholesterol levels in fe-
males more than males [20]. The clinical implications
for TG and CAD is less well studied compared to LDL
levels. There is some associations but not as important
as LDL and cholesterol levels on CAD. Medications that
lower TG such as fenofibrates failed to improve out-
comes compared to statin therapy in patient with CAD.
Thus fenofibrates is indicated only in patients with very
high TG levels despite diet control.
Finally, both T allele and the wildtype allele patients
who were taking atorvastatin along with aspirin showed
the lowest TG levels when compared to patients who
were not on aspirin and/ or atorvastatin. These findings
suggest that aspirin has an effect on TG levels when is
taking with cholesterol medications; yet, further studies
are needed to determine if there is an effect depending
on the presence or absence of T allele. A study that was
done on mice has revealed that aspirin decreases the se-
cretion of VLDL- TG from the liver which in turn re-
duces HFD- induced hypertriglyceridemia supporting
our findings in this study [21].
Conclusion
In summary, we demonstrated that the presence of
c.553G > T (rs2075291) variant in APOA5 gene increases
human plasma TG levels. Nevertheless, T allele is found
to reduce TG levels in CAD patients who are on the
cholesterol medication, atorvastatin. Thus, c.553G > T
variant can be considered as a significant predicator of
hypertriglyceridemia. In addition, it could be used as a
hallmark for the diagnosis and prognosis of CAD.
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